Abstract

Colorectal cancer (CRC) patients suffer from the second highest mortality among all cancer entities. In half of all CRC patients, colorectal cancer liver metastases (CRLM) can be observed. Metastatic colorectal cancer is associated with poor overall survival and limited treatment options. Even after successful surgical resection of the primary tumor, metachronous liver metastases occur in one out of eight cases. The only available curative intended treatment is hepatic resection, but metachronous CRLM frequently recur after approximately 1 year. In this study, we performed a proteome analysis of three recurrent liver metastases of a single CRC patient by mass spectrometry. Despite surgical resection of the primary CRC and adjuvant chemotherapy plus cetuximab treatment, the patient developed three metachronous CRLM which occurred consecutively after 9, 21 and 31 months. We identified a set of 1132 proteins expressed in the three metachronous CRLM, of which 481 were differentially regulated, including 81 proteins that were associated with the extracellular matrix (ECM). 56 ECM associated proteins were identified as upregulated in the third metastasis, 26 (46%) of which were previously described as negative prognostic markers in CRC, including tenascin C, nidogen 1, fibulin 1 and vitronectin. These data may reflect an ascending trend of malignancy from the first to the third metachronous colorectal cancer liver metastasis. Additionally, the results indicate different ECM phenotypes for recurrent metachronous metastasis, associated with different grades of malignancy and highlights the importance of individual analysis of molecular features in different, consecutive metastatic events in a single patient.

Highlights

  • More than 1.8 million cases of colorectal cancer (CRC) were estimated in the year 2018, making CRC the third frequent cancer burden worldwide

  • We have identified for the first time differentially regulated proteins in three metachronous liver metastases from a single patient with colorectal cancer by mass spectrometric analysis

  • CRC patients suffer from the second highest mortality among all cancer entities [1] and colorectal cancer liver metastases (CRLM) can be observed in nearly half of CRC patients [2]

Read more

Summary

Introduction

More than 1.8 million cases of colorectal cancer (CRC) were estimated in the year 2018, making CRC the third frequent cancer burden worldwide. Metachronous liver metastases are present in a lower number of patients ranging from 8 to 13% [5] after excision of the primary tumor. Altered expression of ECM proteins, e.g. the proteoglycan tenascin C (TNC), could be correlated to cancer among a wide variety of tumor entities, including colorectal carcinoma, underlining the importance of the extracellular matrix signatures in cancer [8]. A recent study by Kim et al identified 58 differentially regulated proteins in CRC primary tumors and their respective solitary synchronous CRLM of which many were associated with the ECM [10], suggesting a crucial role of ECM proteins in colorectal cancer liver metastasis. We analyzed the protein composition of three recurrent metachronous liver metastases and the healthy liver tissue of one patient with colorectal cancer using mass spectrometry. FOLFOX chemotherapy scheme was repeated after the first occurrence of liver metastasis

Materials and methods
Results and discussion
Compliance with ethical standards
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call